• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Single high dose versus repeated bone-targeted radionuclide therapy.

作者信息

Liepe K

机构信息

Department of Nuclear Medicine, GH Hospital Frankfurt (Oder), Müllroser Chaussee 7, 15236, Frankfurt (Oder), Germany.

出版信息

Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2144-2145. doi: 10.1007/s00259-017-3815-0. Epub 2017 Aug 31.

DOI:10.1007/s00259-017-3815-0
PMID:28861597
Abstract
摘要

相似文献

1
Single high dose versus repeated bone-targeted radionuclide therapy.单次大剂量与重复骨靶向放射性核素治疗
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2144-2145. doi: 10.1007/s00259-017-3815-0. Epub 2017 Aug 31.
2
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.对“单次大剂量与重复骨靶向放射性核素治疗”的回复
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2.
3
Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy.快速哈特利变换在放射性核素治疗三维剂量计算中的应用。
Med Phys. 1998 Nov;25(11):2226-33. doi: 10.1118/1.598422.
4
Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy.放射性核素在放射免疫治疗中的增殖及长寿命放射性核素的优势
Med Phys. 1998 Jan;25(1):37-42. doi: 10.1118/1.598171.
5
Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.131I标记的CC49多次推注和持续注射用于结肠癌异种移植模型治疗的比较。
Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s.
6
Time-dose-fractionation in radioimmunotherapy: implications for selecting radionuclides.放射免疫治疗中的时间-剂量-分割：对放射性核素选择的影响
J Nucl Med. 1993 Oct;34(10):1801-10.
7
Radiobiology of low-dose-rate radiation relevant to radioimmunotherapy.
Cancer Biother Radiopharm. 2000 Feb;15(1):7-14. doi: 10.1089/cbr.2000.15.7.
8
The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.托西莫单抗和碘I 131托西莫单抗放射免疫治疗中剂量测定的临床重要性。
Semin Oncol. 2003 Apr;30(2 Suppl 4):31-8. doi: 10.1053/sonc.2003.23799.
9
Systemic targeted radionuclide therapy: potential new areas.全身靶向放射性核素治疗：潜在的新领域。
Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S74-82. doi: 10.1016/j.ijrobp.2005.05.029.
10
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.实体瘤放射免疫治疗中高传能线密度（LET）的α发射体与低LET的β发射体对比：人结肠癌模型中213Bi标记与90Y标记的CO17-1A Fab'片段的治疗效果及剂量限制毒性
Cancer Res. 1999 Jun 1;59(11):2635-43.

引用本文的文献

1
Reply to 'Single high dose versus repeated bone-targeted radionuclide therapy'.对“单次大剂量与重复骨靶向放射性核素治疗”的回复
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):515-517. doi: 10.1007/s00259-017-3902-2.

本文引用的文献

1
Phase I/II trials of Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Re-HEDP用于转移性去势抵抗性前列腺癌的I/II期试验：给药活性和剂量测定对生存影响的事后分析
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):620-629. doi: 10.1007/s00259-016-3543-x. Epub 2016 Oct 21.
2
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.镭-223 联合治疗转移性去势抵抗性前列腺癌患者：一项国际性、早期准入、开放标签、单臂 3b 期试验。
Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
3
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
镭-223 二氯化物在有或无基线阿片类药物使用的症状性去势抵抗性前列腺癌患者中的疗效和安全性：来自 3 期 ALSYMPCA 试验的结果。
Eur Urol. 2016 Nov;70(5):875-883. doi: 10.1016/j.eururo.2016.06.002. Epub 2016 Jun 22.
4
Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.前列腺癌激素难治性骨转移重复（188）Re-HEDP 治疗后的姑息治疗和生存：回顾性分析。
J Nucl Med. 2011 Nov;52(11):1721-6. doi: 10.2967/jnumed.111.093674. Epub 2011 Oct 5.
5
A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone.一项关于高活性186Re-HEDP联合自体外周血干细胞移植治疗骨转移的进展期激素难治性前列腺癌的2期研究。
Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1055-61. doi: 10.1007/s00259-005-0010-5. Epub 2006 Mar 30.
6
Palliative radiotherapy in the treatment of skeletal metastases.姑息性放疗在骨骼转移瘤治疗中的应用
Eur J Pain. 2002;6(5):323-30. doi: 10.1016/s1090-3801(02)00028-9.
7
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.高活性铼-186 羟基乙叉二膦酸盐联合自体外周血干细胞解救：一项针对骨转移的进展期激素难治性前列腺癌的 I 期研究。
Br J Cancer. 2002 Jun 5;86(11):1715-20. doi: 10.1038/sj.bjc.6600348.
8
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.晚期雄激素非依赖性前列腺癌的骨靶向治疗：一项随机II期试验
Lancet. 2001 Feb 3;357(9253):336-41. doi: 10.1016/S0140-6736(00)03639-4.